Google
GSK 株価分析 — GLAXOSMITHKLINE PLC ADR (Healthcare >> Drug Manufacturers - General)
GSK に関するよくある質問
GSKのPER（株価収益率）は？
GLAXOSMITHKLINE PLC ADR（GSK）は現在PER 21.64倍で取引されています。
GSKのROE（自己資本利益率）は？
GLAXOSMITHKLINE PLC ADRのROEは27.32%です。
GSKの配当利回りは？
GLAXOSMITHKLINE PLC ADRの配当利回りは3.41%です。
GSKの品質スコア（Quality Score）は？
当社のAIはGSKの総合財務品質を100点中62点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
GSKは今が買い時ですか？
当社AIのタイミングスコアは100点中50点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
GSKはどのセクターに属しますか？
GLAXOSMITHKLINE PLC ADRはHealthcare >> Drug Manufacturers - Generalセクターに分類されます（NYSE市場）
GSK AI Analysis Summary
Our AI summary for GSK: GLAXOSMITHKLINE PLC ADR (NYSE), Healthcare >> Drug Manufacturers - General sector. The stock currently trades at a P/E of 21.64, ROE of 27.32%, a dividend yield of 3.41%. Its financial Quality Score stands at 62/100 — mid-range fundamentals relative to the market. The AI Timing Score is 50/100 — technical signals are mixed; watch for a clearer trend. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 51.69
Price
-0.38
(-0.73%)
Day Change
|
|
|---|
GSK, ファンダメンタルスコアはok ( ファンダメンタル = 62) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- NEUTRAL
- Signal Description
- Company financial health is OK
- Reason
-
ROEの伸びが低い
ROEが昨年度比で低い
ROAがROEに比べて低い
ROAの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not quite good , financial health is not good , and ability to make profit is good , ...
| Deepscope 分析 |
|
51% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | N/A |
| Magic Formula Rank by ROA |
1023
|
| Magic Formula Rank by ROE |
1023
|
| Magic Formula Rank by ROIC |
1217
|
| Price | 51.69 |
| PBV / Sector |
6.07 / 2.68
|
| Earning Per Share | 2.39 |
| PE / Sector |
21.64 / 27.65
|
| PEG or PE/Growth / Sector |
0.28 / 0.28
GREAT
|
| Average 1M Daily Value |
229.78 M
GREAT
|
| Average 1W Daily Value |
301.10 M
GREAT
|
| Timing Factors |
|
42% |
| Financial Health |
|
41% |
| ポイントになる統計 |
|
70% |
| 配当 |
|
54% |
| 登録情報 |
| Analyze Date | 2026-08-01 07:59:56 |
| Symbol | GSK |
| Name | GLAXOSMITHKLINE PLC ADR |
| Sector | Healthcare >> Drug Manufacturers - General |
| Market | NYSE |
| Listed Shares | 2,003.45 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 104,319.44 / 256,404.20 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 79 New Oxford Street, London, United Kingdom, WC1A 1DG
Phone: 44 20 8047 5000
Website: https://www.gsk.com
Employees: 66,841
Description: GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It also provides vaccines for Shingles, Meningitis, RSV, Seasonal Influenza, Hepatitis, Diphtheria, Tetanus, Acellular Pertussis, Rotavirus, Pertussis, Polio, Haemophilus, Invasive Diseases, Pneumonia, Acute Otitis Media, Measles, Mumps, Rubella and Chickenpox, and Human Papilloma Virus. Additionally, the company offers general medicines for asthma, COPD, bacterial infection, benign prostatic hyperplasia, allergic rhinitis, and inflammatory skin conditions. It also focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. It has a collaboration agreement with CureVac to develop mRNA vaccines for infectious diseases; and strategic research collaboration with Engitix Ltd. to identify and validate novel therapeutic targets driving liver fibrosis regression. The company has a strategic alliance with AN2 Therapeutics, Inc. for the development of new therapies for TB. GSK plc was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. The company was founded in 1715 and is headquartered in London, United Kingdom.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Drug Manufacturers - General
Click a bubble to view stock details · Bubble size represents market capitalization share
